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Most of the memoxy-8//-dibenzo[fl,g]isoquinolin-8-ones 3a-h and their acet-
oxy derivatives 6a-e were synthesized by condensation of l-oxo-l,2,3,4-te-
trahydroisoquinolines 4a-c and homophthalic acid anhydrides 5a and b, ether 
cleavage and acetylation. These protoberberinones were tested for cytostatic 
activity in vitro using MDA-MB-231 mammary tumor cells and for interac-
tion with native calf thymus DNA. Tetramethoxy-8-oxoberbine 3f shows an 
inhibition of cell proliferation of 87% at a concentration of 10 
cytostatic effect does not depend on intercalation into DNA. 
r5 mole; its 
Synthese, Antitumoraktivität und DNA-Interaktion von Methoxy- und 
Acetoxy-8-oxoberbinen 
Die meisten der Methoxy-8//-dibenzo[ö,^]chinolizin-8-one 3a-h und ihre 
Acetoxyderjvate 6a-e wurden durch Kondensation der l-Oxo-l,2,3,4-tetra-
hydroisochinoline 4a-c mit den Homophthalsäureanhydriden 5a und b, an-
schließende Etherspaltung und Acetylierung dargestellt. Die cytostatische 
Wirkung dieser Protoberberinone wurde an der MDA-MB-231-Zellinie, die 
DNA-Interaktion an nativer Kalbsthymus-DNA geprüft. Das Tetramethoxy-
8-oxoberbin 3f zeigt eine Hemmung der Zellproliferation von 87% bei einer 
Konzentration von 10"5 M , wobei die cytostatische Wirkung nicht auf eine 
Interkalation mit der DNA zurückzufuhren ist. 
In 1972 Zee-Cheng1^ reported upon inhibitory effects of 
the alkaloid berberine (1, Fig. 1) in various models of leu-
kaemia. This protoberberine derivative is nearly planar and 
characterized by a cationic center. These two properties 
might contribute to the affinity of berberine (1) to DNA 
and to its cytotoxic effect2). Berberine (1) and coralyne (2, 
Fig. 1)3), however, proved to be too toxic for clinical use 
and so further development of this type of alkaloids is 
necessary. 
Based on these findings, we describe the synthesis of 
methoxy- (type 3) and acetoxy-8-oxo-5,6-dihydro-diben-
zo[a,g]quinolizines (type 6), their cytotoxic properties and 
their interaction with DNA. 
H3co, 
H3CO 
of e.g. 2,3,10,1 l-tetramethoxy-5,6-dihydro-87/-dibenzo[a,g]-
quinolizin-8-one (3f), because this approach enabled us to 
react various 1,2,3,4-tetrahydroisoquinoline-l-ones 4 with 
differently substituted homophthalic acid anhydrides 5 
(Scheme 1, see Page 510). 
3-Methoxyphenylacetonitrile was hydrogenated with 
H^/Raney-Ni. Increased pressure (60 atm) and elevated 
temp. (120°C) are mandatory for quantitative yields of 
amine 7a. ß-Phenylethylamines 7a-c were cyclized via the 
pertinent carbamates 8a-c7), obtained from amines 7a-c and 
ethyl chloroformate. Heating the urethanes 8a-c with neat 
polyphosphoric acid affords the tetrahydroisoquinolin-1-
ones 4 (Scheme 2). 
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Figure 1 
Chemistry 
The demand of a large variety of dihydro-dibenzo[a,g]qui-
nolizin-8-ones (3) excludes many synthetic approaches4'5* 
and led us to Haimova's strategy6) used for the preparation 
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Starting from phenylacetic acid 9, the missing 0-CH2-O-
increment was introduced according to Finkelstein and 
Brossi 8 ) . This o-hydroxymethylation led to the isochroman 
10, which was oxidized to the homophthalic acid 11a. Heat-
ing of compounds 11a and b with acetyl chloride led to 
anhydrides 5 (Scheme 3). 
Deviating from this approach 5-methoxyhomophthalic 
acid (lib) was obtained from bromination of /w-methoxy-
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benzoic acid (12) affording 13, and reaction of 13 with ethyl 
acetoacetate/NaH/Cu2Br2 as described as a general syn-
thesis of homophthalic acids by Brugginl?\ As outlined in 
the introduction Haimova's approach6* was used for the syn-
thesis of compounds 3a-f (Scheme 1). 
For reasons of comparison we also synthesized the acet-
oxy derivatives 6a-e. By using BBr3 for the cleavage of the 
methoxy ethers 3 we found a smooth way for getting the 
hydroxy derivatives - the temp, used in this procedure is 
depending on the grade of substitution in the aromatic rings. 
To avoid oxidative degradation of the free phenols we im-
mediately prepared the acetoxy-8-oxo-5,6-dihydro-diben-
zo[tf,g]quinolizines 6 by refluxing with acetic acid anhy-
dride/pyridine (Scheme 1). 
To get the 9,10-dimethoxy-8-oxo-5,6-dihydro-diben-
zo[tf,g]quinolizines 3g and h (Scheme 4) an easy one-step 
synthesis is the alkaline oxidation of quaternary protoberbi-
nium salts, already described by Gadamerl0\ starting from 
berberine- (1) and palmatine chloride (14). 
For further comparison of the cytotoxic properties and 
structure-activity-relationships we also prepared the en-
amine 15 as a crystalline product11* by reduction of com-
pound 3f with UAIH4 (Scheme 5). Further reduction of 15 
with NaBH4 led to racemic xylopinine (16) which was de-
hydrogenated with iodine to the quaternary 2,3,10,11-tetra-
methoxyberbinium iodide 17 (Scheme 5). 
The NMR-Data of the intermediate 2,3,10,11-tetrameth-
oxyenamine 15 were assigned by NOE-difference-spectra. 
Because 5,6-dihydro-8-oxoberbines have a slight angle 
(18-20°, Fig. 2) in the isoquinoline ring system and the 
cytotoxic properties often depend on the planarity of a sub-
stance, we aromatized the 5,6-dihydro-8-oxoberbine 3f by 
dry heating with Pd/C. According to Dreiding-models and 
the rules of aromaticity the resulting 8//-dibenzo[tf,g]qui-
nolizin-8-one 18 (Scheme 4) has a planar ring system with 
18 rc-electrons. 
Fig.2: Deviation from planarity (see text). 
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Cytostatic activity 
The MDA-MB-231 cell line 1 2 ) was used for determination 
of the cytostatic activity. The cells are hormone-inde-
pendent mammary tumor cells of human origin. Al l the 8-
oxoberbines described were tested for cytostatic effects at a 
cone, of 10"5 mole. The inhibition of cell growth was deter-
mined by the microtiter essay with spectroscopic measure-
ment of the living cell density13). 
Most of our compounds were devoid of activity, with the 
exception of 3d and 3f, which had equal or better cytostatic 
properties than berberine (1) and coralyne chloride (2). The 
tetramethoxy-8-oxoberbine 3f was the most active com-
pound. Replacement of the methoxyphenyl ring (ring D) by 
a pyridine ring (1914), Scheme 4) decreased the cytostatic 
activity. 
Table 1: Cytostatic effect on the growth of MDA-MB 231 cells 
Compound % T/C a Compound % T / C a 
1 41 b 6a 99 ns 
2 33 b 6b 76 b 
3a 95 n s 6c 77 b 
3b 99 ns 6d 56 b 
3c 70 b 6e 6 9 b 
3d 44b 16 75 b 
3e 98 n s 17 100 n s 
3f 13b 18 100 n s 
3g 61b 19 89 b 
3h 81 b 23 97 n s 
a Concentration lxl0" 5 M . 
b significant p< 0.01. 
n s not significant. 
Interaction with DNA/RNA 
Interaction of a compound with DNA or RNA often leads to cytostatic 
effects. In this context intercalation has to be distinguished from unspecific 
addition to DNA or RNA. 
Conventional UV-spectroscopy is frequently used for preliminary studies 
of interactions with DNA. Berberine (1), e.g., when incubated with native 
extinction 
DNA, shows three isosbestic points in its UV-spectrum, which according to 
Krey2) might be indicative for a certain affinity of 1 to DNA. Coralyne (2), 
however, does not exhibit an isosbestic point under these conditions, but a 
hypsochromic effect at low concentrations was regarded15) as a hint to-
wards an interaction with DNA; high concentration of 2 leads to a batho-
chromic shift2*. 
In UV-difference spectroscopy even small deviations from 
the spectrum taken without DNA can be recognized by 
shifts of the base line. Sufficient solubility in the DNA-buf-
fer system is a prerequisite for pertinent investigations. We 
tested our dibenzo[a,g]quinolizin-8-ones in comparison 
with ethidium bromide and berberine chloride (1): Most of 
our protoberberines, especially di- and trimethoxy-deriva-
tives did not show any or only weak interactions with native 
DNA. Tetramethoxy-substitution, however, causes inter-
ference (Fig. 3). 
As expected ethidium bromide shows strongest interaction 
efficacy, followed by compound 3f (line 2). Berberine 
chloride (1) was nearly ineffective under these conditions. 
In order to find out whether the interaction of compound 3f 
with DNA depends on its concentration, constant aliquots of 
3f were added to the DNA-solution: linear increase points 
towards a concentration-depending interaction with native 
DNA. After sonication of native DNA ethidium bromide 
has lost its affinity to DNA whilst the difference spectra 
with 3f do not differ from each other. Therefore, we sup-
pose that this protoberberinone affects not only the intact 
DNA but also single DNA-increments. As a consequence 
we tested interferences of 3f with guanosine, cytidine, 
adenosine, uridine, and their 5-phosphates as well as with 
pertinent 2'-desoxy derivatives and thymidine: 3f shows af-
finity to 2'-desoxyguanosine, 2'-desoxycytidine and to their 
phosphates (Fig. 4). 
The interaction with 2'-desoxyadenosine is weak, no ef-
fect was observed with 2'-desoxyuridine and thymidine. 
Therefore, we do not expect any specific affinity to native 
RNA. The cytotoxic trimethoxyprotoberberine 3d does not 
show any interaction with native DNA or its nucleosides. 
wavelength [nm] 
250 300 350 £ 0 0 
Fig. 3: Difference spectra for 1 = ethidium bromide, 2 = 3f, and 3 = berberine chloride; R = [substance]/[DNA] = 1.5 [mole/mole phosphorus]. 
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Fig. 4: Difference spectra for 3f with 1 = 2'-desoxyguanosine, 2 
phosphate. 
2,-desoxyguanosine phosphate, 3 = 2*-desoxycytidine and 4 = 2'-desoxycytidine 
Fluorescence Spectroscopy 
The interaction of 3f with DNA was confirmed by DNA-
induced shift of its fluorescence maximum from 425 nm (3f 
in DMF plus phosphate buffer saline) to 540 nm after incu-
bation with DNA for 2 min (cf. Experimental Part). 
Displacement ofEthidium bromide 
At high concentrations of salts in the buffer system (ca. 1.0 mole) ethi-
dium bromide interacts with DNA by intercalation, whilst at low ionic 
strength additional electrostatic binding occurs, caused by reciprocal ac-
tions of the phosphate increments with the ethidium cation. These two 
effects lead to an increase of fluorescence of the ethidium cation which is 
considered to be a specific test for intercalation16,17*. Addition of another 
intercalating substance displaces ethidium bromide and, therefore, dimi-
nishes or cancels its fluorescence intensity, depending on the concentration 
of the displacing compound. The C50-values (50% fluorescence quenching) 
obtained according to McGhee and von Hippel1® are used to determine 
binding constants of our substances under consideration. 
For our experiments we have used the ratio [DNA = mole 
phosphorus]/[mole ethidium bromide] = 2.0 in order to get 
sufficient fluorescence intensity at the beginning of the titra-
tion. Moreover, a low ionic strength was adjusted to leave 
both opportunities of binding open {vide supra). Experi-
ments were run with those protoberberinones exhibiting sig-
nificant effects at MDA-MB-231 cells (Table 1)19). Actino-
mycin D was used as a positive control20); this compound 
displaces ethidium bromide irreversibly. Fig. 5 shows that 
actinomycin D replaces ethidium bromide, whilst the 
protoberberinones tested do not. 
Viscosity experiments 
Intercalating substances lead to increased length of DNA for about 3.4 A 
by partial unwinding21* accompanied by changing of the torsion angle 
(ethidium bromide, e.g., gives rise to an alteration of a least 12° 2 2 ) ) . At the 
same time intercalation stabilizes DNA so increasing its viscosity. There-
fore, intercalating properties can be determined by titration of DNA with 
the intercalating molecule. By this method intercalation of coralyne (2) into 
native DNA - analogous to that of ethidium bromide - has been detected15). 
Titration of native DNA with protoberberinone 3f indicated 
that this test compound - contrary to ethidium bromide - does 
not increase the relative viscosity of DNA, so corroborating 
the results of the displacement experiment and of the test with 
sonicated DNA. Obviously 3f (and similar protoberberinones?) 
does interfere with native DNA, but not by intercalatioa 
Discussion 
Among the tetramethoxy-8//-dibenzo[a,g]quinolizin-8-
ones, only 3f shows strong cytostatic activity against MDA-
MB-231 human mammary tumor cells with a better effect 
than the original protoberberines berberine (1) or coralyne 
chloride (2). This effect can be rationalized by an interaction 
with DNA. However, a direct intercalation into DNA can be 
ruled out. Based on these findings, we have synthesized C-5-, 
C-6- and C-13-alkylated derivatives to improve these ef-
fects19*. In the case of the acetoxy derivatives, this structural 
modifications should give rise to binding affinity for the es-
trogen receptor, a prerequisite for a selective action on es-
trogen receptor positive tumors like mammary carcinomas19*. 
The authors thank M. Beer and R. Brunner-Ploss for technical assistance 
and the Deutsche Forschungsgemeinschaft (SFB 234) for financial support. 
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Experimental Part 
Melting points: Biichi 510 apparatus, uncorrected.- Elemental analyses: 
Mikroanalytisches Laboratorium, University of Regensburg.- IR-spectra: 
Beckman Acculab III; KBr.- ^-NMR-spectra: Varian EM 390 (90 MHz), 
Bruker WM 250 (250 MHz); TMS as internal standard.- UV-(dif-
ference)spectra: Uvikon 810 (Kontron); solvent: acetonitrile.- Fluores-
cence-spectra: Hitachi F-3000.- Mass-spectra: Varian MAT CH 5. 
Dihydro-dibenzo[a,g]quinolizines3a-f 
1-Oxoisoquinoline 4 (5 mmole) is suspended in chlorobenzene p.a. (15 
ml), pyridine p.a. (0.41 ml) and POCl 3 (0.21 ml in 5 ml chlorobenzene p.a.) 
are added. The suspension is stirred for 15 min at room temp., then ho-
mophthalic acid anhydride 5 (4.55 mmole) is added slowly. The mixture is 
stirred again for 15 min, then re fluxed for 1 h, cooled again and dissolved 
in CH 2C1 2 (50 ml). The org. layer is washed with 10% NaOH (3 x 40 ml), 
dried (Na2S04) and evaporated. The remaining oil is purified by CC (Si0 2; 
EtOAc) and crystallized from ether. The crystals of 3a-f are colorless and 
recrystallized from EtOH.- Yields: 55-70%. 
5,6-Dihydro-2,10-dimethoxy-8H-dibenzo[a,g]quinolizin-8-one (3a) 
3a was synthesized from 4b and 5b; m.p. 152°C- C 1 9 H 1 7 N 0 3 (307.4) 
Calc. C 74.3 H 5.58 N 4.6 Found C 74.0 H 5.55 N 4.4.- IR (KBr): 1645 
(-CO) cm 1 .- *H-NMR (CDC13): 5 (ppm) = 2.88 (t; J = 6 Hz; 2H; -CH 2 - ; 
H-5), 3.80 (s; 3H; -OCH 3), 3.87 (s; 3H; -OCH3), 4.33 (t; J = 6 Hz; 2H; 
-CH 2 - ; H-6), 6.73-7.90 (m; 6H arom and 1H vinyl).- UV: X max (log e) = 
326 (4.27), 255 (4.12), 221 nm (4.26). 
5,6-Dihydro-3,10-dimethoxy-8H-dibenzo[a,g]quinolizin-8-one (3b) 
From 4a and 5b; m.p. 176-177°C- C 1 9 H 1 7 N 0 3 • 1/2 H 2 0 (316.4) Calc. C 
72.2 H 5.73 N 4.4 Found C 72.0 H 5.81 N 4.3.- IR (KBr): 1645 (-CO) 
cm"1.- *H-NMR (CDC13): 8 (ppm) = 2.87 (t; J = 6 Hz; 2H; -CH 2 - ; H-5), 
3.77 (s; 3H; -OCH3), 3.87 (s; 3H; -OCH 3), 4.33 (t; J = 6 Hz; 2H; -CH 2 - ; 
H-6), 6.57-7.92 (m; 6H arom and 1H vinyl).- UV: X max (log e) = 327 
(4.38), 255 (4.17), 214 nm (4.44).- MS: m/z = 307 (100%, M+*), 292 (80, * 
277.73 (M - CH 3) +), 277 (4), 153.5 (10, M 2 + ) . 
5,6-Dihydro-23-dirtethoxy-8H~dibenzo[a,g]quinolizin-8-one (3c) 
From 4c and homophthalic acid anhydride (Fa. Aldrich); m.p. 175°C, lit. 
181-182°C23). 
5,6-Dihydro-3,10,11 'trimethoxy-8H-dibenzo[a,g]quinolizin-8-one (3d) 
From 4a and 5a; m.p. 185-186°C- C 2 0 H 1 9 N O 4 x 1/2 EtOH (360.4) Calc. 
C 70.0 H 6.15 N 3.9 Found C 70.3 H 5.82 N 4.1.- IR (KBr): 1650 (-CO) 
cm"1.- !H-NMR (CDC13): 8 (ppm) = 2.93 (t; J = 6 Hz; 2H; -CH 2 - ; H-5), 
3.82 (s; 3H; -OCH3), 3.97 (s; 6H; -OCH 3), 4.35 (t; J = 6 Hz; 2H; - C H r ; 
H-6), 6.70-7.03 (m; 3H arom and 1H vinyl), 7.60-7.90 (m; 2H arom).- UV: 
X max (log e) = 328 (4.27), 252 (4.31), 218 nm (4.29). 
5,6-Dihydro-23,10-trimethoxy-8H-dibenzo[a,g]quinolizin-8~one (3e) 
From 4c and 5b; m.p. 157-158°C- C 2 oH 1 9 N0 4 (337.4) Calc. C 71.2 H 
5.68 N 4.2 Found C 70.8 H 5.60 N 4.O.- IR (KBr): 1645 (-CO) cm 
*H-NMR (CDCI3): 8 (ppm) = 2.87 (t; J = 6 Hz; 2H; -CH 2 - ; H-5), 3.85 (s; 
6H; -OCH3), 3.93 (s; 3H; -OCH3), 4.32 (t; J = 6 Hz; 2H; -CH 2 - ; H-6), 6.65, 
6.77 (s; 1H arom and 1H vinyl), 7.07-7.53 (m; 3H arom), 7.77 (d; J = 2 Hz; 
1H arom; H-9).- UV: X max (log e) = 322 (4.31), 256 (4.04), 217 nm 
(4.25). 
5,6-DihydrO'2^,10,ll'tetramethoxy'8H-dibenzo[a,g]quinolizin'8'One 
(3f) 
From 4c and 5a; m.p. 194°C, lit. ^ O X 2 4 * . - MS: m/z = 367 (100%, M+"), 
352 (54, * 337.61 (M - CH 3) +), 183.5 (23, M 2 + ) . 
Lactams 4a-c 
Polyphosphoric acid (100 g) is preheated to 140°C (oil bath temp.). After 
reaching this temp, carbamate 8 (50 mmole) is directly poured onto the 
polyphosphoric acid and refluxed for 1 h. After cooling the mixture is 
suspended in ice water (100 ml). While cooling the solution is alkalized 
with NaOH (40%) and extracted with CH 2C1 2 (6 x 150 ml). The combined 
org. layers are dried (Na2S04) and evaporated. The remaining oil is puri-
fied by CC (Si0 2; EtOAc) and crystallized from ether. The crystals of 4a-c 
are colorless and recrystallized from ether.- Yields: 50-60%. 
123\4-Tetrahydro-6-methoxy-l-oxo-isoquinoline (4a) 
Prepared from 8a; m.p. 139°C, lit. B ^ C 2 5 * . - UV: X max (log e) = 285 
(3.35), 250 nm (4.09). 
123,4'Tetrahydro-7-methoxy-l-oxo-isoquinoline (4b) 
From 8b; m.p. 86°C, lit. S M & C ? ® . - UV: X max (log e) = 299 (3.37), 
229 nm (3.96). 
123,4-Tetrahydro-6,7-dimethoxy-l-oxo-isoquinoline (4c) 
From 8c; m.p. 174°C, lit. 173.5-1 T ^ S 0 ^ . - UV: X max (log e) = 293 
(3.76), 255 nm (3.94). 
Carbamates 8a-c 
100 mmole of the corresponding ß-phenylethylamine 7 are dissolved 
with NEt 3 (10.0 g) in absol. CH 2C1 2 (50 ml). After addition of ethyl chloro-
formate (10.8 g) in 50 ml absol. CH 2C1 2 the mixture is stirred for 1 h. The 
precipitate is dissolved with 2 N HCl and stirred again. After washing with 
H 2 0 the org. layer is dried (Na2S04) and evaporated. The remaining oils or 
precipitates are used without further purification.- Yields: nearly quantita-
tive. 
Ethyl-N-[2-(3-methoxyphenyl)ethyl)-carbamate (8a) 
Prepared from 7a and ethyl chloroformate (Fa. Aldrich); C 1 2 H 1 7 N 0 3 
(223.3).- IR (film): 3340 (-NH-), 1710 (-CO) cm"1.- *H-NMR (CDC13): 5 
(ppm) = 1.25 (t; J = 7.5 Hz; 3H; -CH 3), 2.80 (t; J = 7.5 Hz; 2H; -Qfe-CHr 
NH-), 3.40 ("q"; J = 7.5 Hz; 2H; -CH2-CÜ2-NH-), 3.77 (s; 3H; -OCH3), 
4.10 (q; J = 7.5 Hz; 2H; -CH2-CH3), 4.90 (s broad; 1H; -NH-; not ex-
changeable), 6.67-7.40 (m; 4H arom). 
Ethyl-N-[2-(4-methoxyphenyl)ethyll-carbamate (8b) 
From ß-(p-methoxyphenyl)ethylamine and ethyl chloroformate; colorless 
crystals, m.p. 45°C (ether).- C 1 2 H 1 7 N 0 3 (223.3) Calc. C 64.6 H 7.67 N 6.3 
Found C 64.4 H 7.64 N 6.2.- IR (KBr): 3340 (-NH-), 1710 (-CO) cm"1.-
'H-NMR (CDC13): 8 (ppm) = 1.20 (t; J = 7.5 Hz; 3H; -CHj-Qk), 2.70 
(t; J = 7.5 Hz; 2H; -Cifc-CHj-NH-), 3.40 ("q"; J = 7.5 Hz; 2H; -CH 2 -CHr 
NH-), 3.77 (s; 3H; -OCH3), 4.10 (q; J = 7.5 Hz; 2H; -CHrCH 3 ) , 4.67 
(s broad; 1H; -NH-; not exchangeable), 6.70-7.33 (m; 4H arom). 
Ethyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-carbamate (8c) 
From homoveratrylamine (Fa. Fluka) and ethyl chloroformate; white 
solid, m.p. 61 -62°C (ether), lit. 64-66°C 2 8 ). 
/ -Amino-2-(3-methoxyphenyl)ethane (7a) 
200 mmole 3-methoxyphenylaeetonitrile (Fa. Fluka), dissolved in EtOH 
(150 ml, saturated with NH 3) are hydrogenated in the presence of Raney-Ni 
(from 1.5 g alloy) at 60 atm and 120°C for about 4 h. The catalyst is 
filtered off, washed with EtOH and the solvent is evaporated: pure, color-
less oil, b.p. 87°C, 0.2 T; lit. 122-123°C, 7 mm 2 9 ).- Yield: 90-95%. 
lsochroman-1 3-diones 5a and b 
A suspension of homophthalic acid 11 (15 mmole) and acetylchloride 
(30 ml) are refluxed under stirring for 1 h, then the excess of reagent is 
distilled off. 25 ml of absol. ether are added to the residue, the crystallized 
product is washed with ether and dried.- Yields: 60-65%. 
6,7-Dimethoxy-isochroman-l 3-dione (5a) 
Prepared from 11a; colorless crystals, m.p. 174-176°C (ether), lit. 
7-Methoxy-isochroman-l 3-dione (5b) 
From lib; light-brown crystals, m.p. 131-134°C (ether), lit. 142-
143°C3 1 ). 
6 ,7-Dimethoxyisochroman-3-one (10) 
3,4-Dimethoxyphenylacetic acid (9) (200 mmole; Fa. Merck) is heated 
with glacial acetic acid (200 ml) on the steam bath. Formaline solution 
(37%, 40 ml) and cone. HCl (40 ml) are added and the mixture is stirred on 
the steam bath under reflux for 1 h. H 2 0 (200 ml) is added, the solution is 
extracted with CHC13 (3 x 200 ml). The combined org. layers are washed 
with 10% NaHC03-solution, dried (Na2S04) and evaporated. The residue 
is crystallized by adding some drops of EtOH or ether.- Yield: 90%.-
Colorless crystals, m.p. 98-99°C (EtOH), lit. 102-103°C32). 
4 3-Dimethoxyhomophthalic acid (11a) 
100 mmole lactone 10 are dissolved in 10% KOH/H 2 0 (110 ml). Under 
stirring 2% KMn04-solution (1600 ml) is added quickly, the solution is 
stirred at room temp, for 10 h. EtOH (20 ml) is added and the mixture is 
heated on the steam bath. After filtration the water layer is concentrated 
and acidified with cone. HCl. The precipitate is recrystallized from H 2 0.-
Yield: 90-95%.- Colorless crystals, m.p. 206-208°C (H 20), lit. 213-
214°C 3 2 ). 
2-Bromo-5-methoxybenzoic acid (13) 
0.24 mole of m-anisic acid (Fa. Aldrich) are dissolved in NaOH/H 20 
(10.7 g/267.5 mmole NaOH in 400 ml H 2 0). After heating to 50-60°C 12.9 
ml (0.25 mole) of Br 2 are added slowly, then the solution is stirred for 30 
min. While cooling NaHS03-solution is added until the mixture is color-
less. The precipitate is dried.- Yield: 70-80%.- Colorless crystals, m.p. 
157-158°C (EtOH 96%), lit. 162°C 3 1 ). 
5-Methoxyhomophthalic acid (1 lb) 
lib is prepared from 13 according to Brugginl?\- Yield: 60-70%; light-
brown crystals, m.p. 184-186°C(CH2Cl2/MeOH/H20), lit. 184-186°C9). 
Acetoxy-dihydro-dibenzo[a,g]quinolizines6sL-e 
a) Ether cleavage 
100 mg methoxyoxoberbine 3 (in 10 ml of absol. CH2C12) are added 
dropwise to 0.1 ml of BBr 3 in 10 ml of absol. CH 2C1 2, then refluxed for 1 h 
and stirred at room temp, for 12 h. While cooling saturated NaHC03-solu-
tion (10-15 ml) is added and the suspension is mixed with EtOAc to get a 
clear solution. The org. layer is separated, the water layer is extracted again 
with EtOAc (2 x 50 ml). The combined org. layer are washed with satu-
rated NaCl-solution, dried (Na2S04) and evaporated. Generally the residue 
is dried for a short time i . vac, then it is acetylated immediately. 
b) Acetylation 
The residue from a) is refluxed with A c 2 0 (6 ml) and absol. pyridine (5 
drops) for 2 h, then the excess of reagents is evaporated i . vac. After 
cooling the remaining oil is crystallized from MeOH and the precipitate is 
washed with ether and dried. Purification: CC (Si0 2, EtOAc).- Yields: 
70-80% colorless crystals. 
2,10-Diacetoxy-5,6-dihydro-8H-dibenzo[a,g]quinolizin-8-one (6a) 
Prepared from 3a; m.p. 168-169°C (MeOH).- C 2 1 H 1 7 N 0 5 • 1/2 CH 3 OH 
(379.4) Calc. C 68.1 H 5.05 N 3.7 Found C 68.4 H 4.90 N 3.8.- IR (KBr): 
1750 (CH3-CO), 1660 (-CO) cm"1.- ! H-NMR (CDC13): 5 (ppm) = 2.30 (s; 
6H; H3C-CO-), 2.97 (t; J = 6 Hz; 2H; -CH 2 - ; H-5), 4.35 (t; J = 6 Hz; 2H; 
-CH 2 - ; H-6), 6.87-7.63 (m; 5H arom and 1H vinyl), 8.10 (d; J = 2 Hz; 1H 
arom; H-9).- UV: X max (log e) = 329 (4.28), 212 nm (4.40). 
3,10-Diacetoxy-5,6-dihydro-8H-dibenzo[a,g]quinolizin-8-one (6b) 
From 3b; m.p. 206-208°C (MeOH).- C 2 1 H 1 7 N 0 5 (363.4) Calc. C 69.4 H 
4.72 N 3.9 Found C 69.1 H 4.83 N 3.9.- IR (KBr): 1750 (CH3-CO), 1640 
(-CO) cm"1.- !H-NMR (CDC13): 8 (ppm) = 2.33 (s; 6H; H3C-CO-), 3.00 (t; 
J = 6 Hz; 2H; -CH 2 - ; H-5), 4.42 (t; J = 6 Hz; 2H; -CH 2 -; H-6), 6.90-8.20 
(m; 6H arom and 1H vinyl).- UV: X max (log e) = 331 (4.34), 209 nm (4.79). 
3,10,11-Triacetoxy-5,6-dihydro-8H-dibenzo[a,g]quinolizin-8-one (6c) 
From 3d; m.p. 217-219°C (MeOH).- C 2 3 H 1 9 N07 • 1/2 CH 3 OH (437.4) 
Calc. C 64.5 H 4.84 N 3.2 Found C 64.7 H 4.73 N 3.0.- IR (KBr): 1775 
(CH3-CO), 1645 (-CO) cm"1.- ! H-NMR (CDC13): 8 (ppm) = 2.32 (s; 9H; 
H 3C-CO-), 2.93 (t; J = 6 Hz; 2H; - C H r ; H-5), 4.32 (t; J = 6 Hz; 2H; -CH 2 - ; 
H-6), 6.92 (d; J = 2 Hz; 1H arom; H-4), 7.00-7.12 (m; 1H arom and 1H 
vinyl), 7.42 (s; 1H arom), 7.78 (dd; J 1 / 2 = 9/2 Hz; 1H arom; H-2), 8.22 (s; 
1H arom).- UV: X max (log e) = 326 (4.32), 216 nm (4.33). 
23,10-Triacetoxy-5,6-dihydro-8H-dibenzo[a,g]quinolizin-8-one (6d) 
From 3e; m.p. 202-205°C (MeOH).- C 2 3 H 1 9 N 0 7 • 1/2 H 2 0 (430.4) Calc. 
C 64.1 H 4.68 N 3.3 Found C 63.8 H 4.66 N 3.0.- IR (KBr): 1765; 1775 
(CH3-CO), 1660 (-CO) cm"1.- ^ - N M R (CDC13): 8 (ppm) = 2.17 (s; 3H; 
H3C-CO-), 2.30 (s; 6H; H3C-CO-), 2.97 (t; J = 6 Hz; 2H; -CH 2 -; H-5), 4.35 
(t; J = 6 Hz; 2H; -CH 2 - ; H-6), 6.93 (s broad; 1H vinyl; H-13), 7.13 (s 
broad; 1H arom), 7.43 ("d"; J «= 2 Hz; 1H arom), 7.53 (s; 1H arom), 7.63 (s; 
1H arom), 8.08 (d; J = 2 Hz; 1H arom; H-9).- UV: X max (log e) = 330 (4.30), 
215 nm (4.37). 
23,10,11 -Tetraacetoxy-5,6-dihydro-8H-dibenzo[a,g]quinolizin-8-one(6e) 
From 3f; m.p. 244-245°C (MeOH).- C 2 5 H 2 1 N 0 9 (479.4) Calc. C 62.6 H 
4.41 N 2.9 Found C 62.2 H 4.04 N 2.8.- IR (KBr): 1775 (CH3-CO), 1655 
(-CO) cm"1.- ]H-NMR (CDCty: 8 (ppm) = 2.30 (s; 12H; H3C-CO-), 2.96 
(t; J = 6 Hz; 2H, - C H r ; H-5), 4.33 (t; J = 6 Hz; 2H; -CH 2 - ; H-6), 6.87, 
7.12, 7.41, 7.61, 8.20 (s; 4H arom and 1H vinyl).- UV: X max (log e) = 329 
(4.34), 216 nm (4.37). 
Dihydro-dibenzo[a,g]quinolizines3g and h 
To 50 mmole berberin- (1) or palmatine chloride (14), dissolved in hot 
H 2 0 (500 ml), are dropped 150 g KOH in 70 ml H 2 0 . The mixture is 
stirred for 15 min and extracted with ether (3 x 500 ml). The black-brown 
precipitate is stirred with hot ether for 15 min and filtrated. The combined 
ether layers are washed with water, dried (Na2S04) and evaporated. Purifi-
cation: CC (Si0 2, EtOAc).- Yields: 40-50%. 
5,6-Dihydro-9,10-dimethoxy-23-methylendioxy-8H-dibenzo[a,g]-
quinolizin-8-one (3g) 
From berberine chloride (Fa. Sigma); white-yellow crystals, m.p. 188-
190°C (EtOH), lit. 199.5°C33). 
5,6-Dihydro-23,9,10-tetramethoxy-8H-dibenzo[a,g]quinolizin-8-one (3h) 
From palmatine chloride (Fa. Sigma); yellow foam, m.p. 183-184°C 
(EtOH, lit. 183°C34).- C 2 1 H 2 1 N 0 5 • 1/2 EtOH (390.4) Calc. C 67.7 H 6.15 
N 3.6 Found C 67.7 H 5.87 N 3.5.- IR (KBr): 1655 (-CO) cm*1.- !H-NMR 
(250 MHz, CDC13): 8 (ppm) = 2.90 (t; J = 6Hz; 2H; -CH 2 - ; H-5), 3.88, 
3.93, 3.97, 4.00 (s; 12H; -OCH3), 4.33 (t; J = 6 Hz; 2H; -CH 2 - ; H-6), 6.73, 
6.78 (s; 2H arom), 7.23-7.32 (m; 2H arom and 1H vinyl).- UV: X max (log 
e) = 327 (4.26), 217 nm (4.26). 
5,6-Dihydro-2 3,10,11-tetramethoxy-8H-dibenzo[a,g]quinolizine(\S) 
The enamine 15 is prepared from the 8-oxoberbine 3f according to Kipa-
rissidesu\ Yield: 85-90%; yellow precipitate, C 2 1 H 2 3 N 0 4 (353.4), m.p. 
192-195°C (dec), lit. 173-176°CU).- NOE-difference-spectra (250 MHz): 
a) Enamine: 2.90 (t; J = 6 Hz; 2H; -CH 2 - ; H-5), 3.13 (t; J = 6 Hz; 2H; 
-CH 2 - ; H-6), 3.87, 3.88, 3.89 (s; 9H; -OCH3), 3.94 (s; 3H; -OCH 3 , C-2 or 
C-11), 4.13 (s; 2H; -CH 2 - ; H-8), 6.03 (s; 1H vinyl; H-13), 6.60 (s; 1H 
arom; H-4), 6.62 (s; 1H arom; H-l or H-12), 6.63 (s; 1H arom; H-9), 7.12 
(s; 1H arom; H-l or H-12).- UV: X max (log e) = 375 (4.13), 343 (4.09), 
285 (4.35), 263 nm (4.19).- MS: m/z = 353 (81%, M + ) , 352 (100, * 351.00 
(M - H)+), 338 (20, (M - CH 3) +), 337 (10, * 322.64 (352 - CH 3 ) + ) , 336 (21, 
* 335.00 (337 - H)+), 322 (5), 308 (7), 279 (8), 192 (18), 176.5 (10, M 2 + ) . 
b) lminium-Salt, trifluoroacetate: 3.19 (t; J = 7.8 Hz; 2H; -CH 2 - ; H-5), 
3.88 (s; 3H; -OCH 3; C-10), 3.89, 3.98 (s; 6H; -OCH 3; C-2/C-11), 4.02 (s; 
3H; -OCH 3; C-3), 4.14 (t; J = 7.8 Hz; 2H; -CH 2 - ; H-6), 4.47 (s [broad]; 2H; 
-CH 2 - ; H-13), 5.05 (t; J = 3.8 Hz; 2H; -CH 2 - ; H-8), 6.75 (s; 1H arom; H-4), 
6.81 (s; 1H arom; H-l or H-12), 6.87 (s; 1H arom; H-4), 7.35 (s; 1H arom; 
H-l or H-12).- UV (acetonitrile plus HCl): X max (log e) = 341 (4.41), 287 
(4.35), 239 nm (4.27). 
(±)-Xylopinine (16) 
(±)-Xylopinine (16) is prepared from enamine 15 according to Kipa-
rissidesu\- Purification: CC (Si0 2, EtOAc).- Yield: 70-80%, yellow crys-
tals, m.p. 161-163°C (EtOH), lit. 156-157°CU ). 
2 3,10,11-Tetramethoxyberbinium iodide (17) 
300 mg (±)-Xylopinine (16) (0.82 mmole) are dissolved in absol. MeOH 
(25 ml) under N 2 . To the refluxing solution are added 0.64 g I 2 in 30 ml 
absol. MeOH until the suspension turned brownish. After refluxing for 30 
min NaHS03-solution is added until a yellow colour remains. The yellow 
precipitate is washed with water and ether and dried.- Yield: 80-90%, 
yellow crystals, m.p. 255°C (dec, EtOH/H20), lit. 245°C (dec.)35). 
23,10,11 -Tetramethoxy-8H-dibenzo[a,g]quinolizin-8-one (18) 
300 mg 5,6-Dihydro-8-oxoberbine 3f are mixed thoroughly with 300 mg 
of Pd/C (10%) under N 2 for 15 min. The mixture is heated in an oil bath 
(bath temp. 220°C) for 1 h. After cooling the product is separated from the 
catalyst by extraction with CH 2C1 2 and filtration. The org. layer is evap-
orated and dried.- Purification: CC (Si0 2, EtOAc) or PTLC (Si0 2, ethers-
Yield: 80-90%; yellow crystals, m.p. 192-194°C (EtOH), lit. 196-
197°C3 6 ).- IR (KBr): 1650 (-CO) cm"1.- ! H-NMR (CDC13): 8 (ppm) = 3.98 
(s; 3H; -OCH 3), 4.03 (s; 6H; -OCH3), 4.08 (s; 3H; -OCH 3), 6.37 (d; J = 7.5 
Hz; 1H; H-5), 6.85, 6.97, 7.17, 7.50, 7.82 (s; 4H arom and 1H vinyl), 8.35 
(d; J = 7.5 Hz, 1H; H-6).- UV: X max (log e) = 422 (3.97), 398 (4.07), 376 
(4.04), 293 (4.42), 261 (4,41), 224 nm (4.47). 
10-Aza-5,6-dihydro-23-dimethoxy-8H-dibenzo[a,g]quinolizin-8-one(19) 
3 7 \ 
Prepared from 3,4-dihydro-6,7-dimethoxy-l-methyl-isoquinoline ' and 
nicotinic acid chloride according to Lenzl4\- Yield: 40%.- Yellow-orange 
crystals, m.p. 162-165°C (EtOH), lit. 169-172°C14). 
Biological methods 
MDA-MB 231 Human Breast Cancer Cellsl2) 
Cells were grown in McCoy medium (Fa. Boehringer, Mannheim) sup-
plemented with 10% newborn calf serum (NCS, Fa. Gibco), gentamicin (40 
\ig/m\) and NaHC0 3 (2.2 g/1, pH = 7.35). Cells were grown in a humidified 
incubator in 5% C 0 2 at 37°C and harvested with 0.05% trypsine-0.02% 
EDTA in 0.15 M NaCl. At the beginning of the experiment the cell suspen-
sion is switched to 96-holes mikrotitre dishes (100 pJ/hole). After 2-3 days 
of incubation at 37°C the medium is changed to substance-containing me-
dium. Control holes (16/dish) are containing 0.1% of the pertinent solvent 
only. The starting cell density is determined by adding vinblastine in 18 
holes. After further incubation (3 days) the medium is removed and gluta-
raldehyde (100 jxl) in phosphated buffer saline (PBS) (1%) is added for fixa-
tion. After 15 min the aldehyde is decanted and after 25 min the cells are co-
lored with 100 ul of a crystal violet-solution (0.02% in H 20). After this sol-
ution is decanted the cells are washed with H 2 0 for a few times to remove 
unused staining. After addition of 100 |xl EtOH the dishes are shaken for 1 
h. The optical density is determined in a microtitre dish-autoreader EL 309 
(Bio-tek) at 578 nm, the data are processed on an Olivetti M24-PC 1 3 ). 
UV-Difference-Spectroscopy 
a) Interaction with native DNA 
Calfthymus-DNA type I (Fa. Sigma) is dissolved in 0.1-M-Tris-NaCl-
buffer (pH 7.4) at 4°C. The concentration of the solution is about 6 x 10"5 
M (according to phosphorus). Test substances are dissolved in DMSO (10 2 
M solution). Tandem quartz-cells (Fa. Helma) are used. Test- and refer-
ence-cuvette are containing the DNA-solution in one part, in the other part 
only buffer. 1 u.1 of the substance-solution is added to the DNA in the 
test-cell and to the buffer in the reference-cell, respectively. The mixture is 
incubated for 2 min and after cautious stirring the extinction difference is 
determined between 550 and 230 nm. A solution of ethidium bromide (10"2 
M) is used as positive control and in order to limit the volume of solvent 10 
x 1 u.1 substance solution are added at the outmost. To determine a concen-
tration dependence (linear increase of the plot) of the interaction between 
substance and DNA, the extinction is plotted versus the quotient from 
substance concentration and DNA-phosphorus concentration. 
b) Interaction with sonicated DNA 
The experiment is performed according to a). To destroy the DNA-struc-
ture the DNA-solution (see above) is sonicated for 10 min at room temp. 
For evaluation of the spectra identical concentrations of substances are 
compared (native/sonicated DNA). 
c) Interaction with (non-)phosphorylatedDNA-increments 
The experiment is performed according to a), but a solution of (non-) 
phosphorylated DNA-increments (10"2 M) is used instead of the DNA solu-
tion. 
Fluorescence Spectroscopy 
To determine a DNA-induced shift in the fluorescence spectra of our 
substances we measured the spectra with 5 jxl substance solution (10"2 
M/DMF) in phosphated buffer saline and of 5 ul substance solution + 5 u.1 
DNA solution (ca. 4.6 x 10"5 M , according to phosphorus) in PBS between 
600 and 330 nm, respectively.- Excitement wavelength: 265 nm; excite-
ment bandpass: 5 nm; emission bandpass: 5 nm; scan speed: 600 nm/min. 
Displacement of Ethidium bromide 
To get sufficient fluorescence intensity at the beginning of the titration 
we used the ratio [DNA = mole phosphorus]/[mole ethidium bromide] = 
2.0. The concentration of the DNA solution (in 0.1-M-Tris-NaCl-buffer, ph 
7.4) was 4.6 x 10"5 M (according to phosphorus), the concentration of 
ethidium bromide 10"2 M (in DMF), actinomycin D (10"2 M/DMF) was 
used as a positive control. In the experiments aliquots of the test substance 
solutions are added to the ethidium bromide-DNA solution, and after mix-
ing the quenching of fluorescence intensity is determined.- Excitement 
wavelength: 546 nm; emission wavelength: 590 nm; excitement bandpass: 
5 nm; emission bandpass: 5 nm. 
Viscosity Experiments 
For this experiment an Osfwa/d-viscosimeter (No. I) is used, the concen-
tration of the DNA solution (in 0.1-M-Tris-NaCl-buffer, pH 7.4) was 4.6 x 
10"5 M (according to phosphorus). The concentration of the test substances 
was 10"2 M (in DMF). In order to find the apparatus constant the sinking 
time in the buffer was determined, which was equal to that of water. The 
apparatus constant is calculated according to the following usual formula: 
= k • t 
y = kinematic viscosity, rj = dynamic viscosity, p = density, k = appara-
tus constant, t = sinking time. 
As basic value for the sinking time the DNA-solution was measured. By 
addition of aliquots from the substance solution to the DNA-solution in the 
viscosimeter the ratio between substance- and DNA concentration was 
raised from 0.01 to 0.1 with compensation of the solvent effects. From this 
experiment the corrected time for the measurements is resulting: 
Corrected time = t D N A + D M F - t D N A 
The corrected time is substracted from the sinking time of the substance 
solutions, the resulting value is the corrected sinking time for the substan-
ces. Now it is possible to calculate the kinematic viscosity y. 
= k • t' 
Y = kinematic viscosity, rj = dynamic viscosity, p = density, k = appara-
tus constant, t' = corrected sinking time. 
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